Cassava CEO Remi Barbier
August 27, 2021 09:23 AM EDTUpdated 10:53 AM
R&D

The Cas­sa­va saga con­tin­ues as test­ing part­ner de­nies prepar­ing taint­ed Alzheimer's da­ta

Kyle Blankenship

The news keeps get­ting worse over at Cas­sa­va Sci­ences.

In a state­ment Fri­day, test­ing com­pa­ny Quan­ter­ix de­nied in­ter­pret­ing or prepar­ing key …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times